New York Hospital Queens, Flushing, USA.
Am J Mens Health. 2012 Jan;6(1):51-8. doi: 10.1177/1557988311416495. Epub 2011 Aug 10.
The aim of this study was to review the clinical presentation and to evaluate prognostic factors, treatment modalities, outcome, and second malignancy in male breast cancer patients. A chart review was conducted of all men treated for breast cancer between January 1991 and December 2007. Cox proportional hazards regression model and Kaplan-Meier curve were used to determine prognostic factors and plot survival probabilities. Invasive carcinoma was diagnosed in 22 patients and ductal carcinoma in situ in 7 patients. With mortality as the endpoint, tumor size indicated hazard ratio (HR) of 1.5 for each 1-cm increase in tumor size (p = .03). Overall stage and increased age were associated with increased risk of mortality (HR = 2.1, p = .055; HR = 1.09 for a 1-year increase in age, p = .08, respectively). Adjuvant radiation therapy yielded an HR of 0.1 (p = .058), indicating a favorable association with the survival. Advanced age, higher stage, and increasing tumor size were unfavorable to survival in male breast carcinoma. The benefit of adjuvant radiation therapy should be addressed in future collaborative studies.
本研究旨在回顾男性乳腺癌患者的临床表现,评估预后因素、治疗方式、结局和第二恶性肿瘤。对 1991 年 1 月至 2007 年 12 月期间所有接受乳腺癌治疗的男性患者进行了图表回顾。采用 Cox 比例风险回归模型和 Kaplan-Meier 曲线确定预后因素并绘制生存概率。诊断为浸润性癌 22 例,导管原位癌 7 例。以死亡率为终点,肿瘤大小每增加 1cm,风险比(HR)增加 1.5(p =.03)。总分期和年龄增加与死亡率增加相关(HR = 2.1,p =.055;年龄每增加 1 岁,HR = 1.09,p =.08)。辅助放疗的 HR 为 0.1(p =.058),表明与生存呈有利关联。年龄较大、分期较高和肿瘤大小增加对男性乳腺癌的生存不利。在未来的合作研究中,应探讨辅助放疗的益处。